Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, ...
Mirai Bio to Unveil Two Next Generation Programs for Targeted Nucleic Acid Delivery Beyond the Liver at ASGCT 2026 ...
For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results